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Introduction
Nicotinic acetylcholine receptors (nAChRs) containing the α7 subunit are widely expressed in human brain regions associated with cognitive functions [1] [2] [3] . This subtype of nAChR has major pre-synaptic roles in the brain [4] , which include regulating the release of dopamine from nerve terminals in the dopaminergic reward pathway [5, 6] . The activation of α7 nAChRs is neuroprotective against toxicity resulting from exposure to the neurotoxic β-amyloid peptide, Aβ1-42, important in Alzheimer's disease and other toxins [7] . The α7 nAChRs participate in auditory sensory gating, defects in which contribute to the attention and cognitive problems associated with schizophrenia [8, 9] . They are also involved in the mechanism of nicotine addiction [10] . The α7 nAChR subunit, which forms robust functional homomeric receptors, has been proposed as a candidate target for new drugs designed to ameliorate symptoms of Alzheimer's disease and schizophrenia as well as to control pain [11] .
A number of α7-specific agonists have been designed with therapeutic goals in mind but this strategy raises concerns relating to long-term drug activation and / or rapid desensitization of nAChRs, which may compromise the utility of such ligands. In attempts to circumvent such problems, positive allosteric modulators of the α7 nAChR have been generated, which act by enhancing the actions of the neurotransmitter acetylcholine (ACh) [11] . Such drugs offer a therapeutic approach to cognitive and attention deficits, which, importantly, preserve the integrity of cholinergic neurotransmission [12] . Two classes of positive allosteric modulators (PAMs) can be recognised in terms of their actions on α7 nAChRs [11, 13] . Type I PAMs enhance the amplitude of the response to ACh with little or no effect on the time-course of the response, including desensitization. Examples include ivermectin (IVM), genistein, 5-hydroxyindole (5-HI), compound-6 and NS-1738. Type II PAMs, such as PNU-120596, and the
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A c c e p t e d M a n u s c r i p t tetrahydroquinoline, 4-naphthalene-1-yl-3a,4,5,9b-tetrahydro-3-H-cyclopenta[c]quinoline-8-sulfonic acid amide (TQS). In addition to enhancing the amplitude of ACh responses, Type II PAMs also greatly prolong the time-course of α7-mediated ACh responses [13] .
The discovery that NS-1738 and PNU-120596 are selective for α7, yet show quite different PAM actions suggests that different sites of action on the receptor may exist [14] . Regions important in the actions of these drugs have been explored using chimeras of the α7 and the 5-HT3A cys-loop receptor subunits, both of which exhibit homomer-forming capacity. Based on studies of PNU-120596 and NS-1738, Bertrand and colleagues conclude that there may be different binding sites for different allosteric modulators, each with a distinct profile of drug sensitivities [14] . They also highlight an important role in the actions of these allosteric modulators [14] of a short sequence (AEIMPATSDS) in human α7 at the M2 / M2-M3 loop interface, equivalent to the region (SDTLPATAIG) of the 5-HT3A receptor. In a separate study, Millar and colleagues have suggested that there may be a common site of action for two PAMs PNU-120596 and LY-2087101 [15] . These authors also used α7 / 5-HT3 chimeras, identifying the transmembrane (TM) regions as critical in drug enhancement of agonist evoked responses. In particular, 5 residues (2 in TM1, 1 in TM2 and 2 in TM4) strongly influence the actions of PAMs. Although mutating all these residues in the α7 TM sequence to their 5HT3A equivalents strongly reduced the allosteric actions of these drugs, such activity could not be restored by incorporating the 7 resides into the equivalent site of the 5-HT3A receptor subunit.
. Experiments on chimeras have been extremely fruitful but are not without their problems. For example, some are poorly expressed, suggesting that they may not be correctly folded, thereby A c c e p t e d M a n u s c r i p t complicating interpretation of the results. In addition, the functional organization of receptor domains may not be perfectly modular, so that the effects of substituting a domain may include indirect effects on other, unchanged domains. This may be a particular concern when interspecies chimaeras are used. A complementary approach is to explore the comparative pharmacology of evolutionarily remote members of the same superfamily of cys-loop ligandgated ion channels. This strategy has already proved instructive in accelerating the identification of drug targets. For example, the hitherto elusive steroid site on the GABA receptor was identified in a comprehensive comparison between Drosophila melanogaster GABA-gated chloride channels and human GABA A type receptors [16] . We have previously shown that the anthelmintic compound, IVM, enhanced ACh-induced 7 amplitude responses, confirming the earlier finding of Bertrand and colleagues [17] , while slightly attenuating responses of ACR-16 [18] , a Caenorhabditis elegans α7 homologue [19, 20] . ACR-16 and 7 nAChR subunits share considerable amino acid sequence identity of 47% but show important differences in residues considered important in allosteric drug actions (Fig. 1) . For example, of the 5 transmembrane residues identified by Millar and colleagues in rat 7 (S222, A225, M253, F455 and C459 using mature peptide numbering) only F455 is conserved in C. elegans ACR-16 (F458 in ACR-16, Fig.1 ) [15] . Here, we report comparison of the actions of several other PAMs on the human 7 nAChR and ACR-16. Having established that these two receptors differ greatly in their sensitivity to PAMs, we then modeled the docking of IVM to the transmembrane regions of both receptors in an initial attempt to develop a molecular interpretation of the observed differences in pharmacology.
Materials and Methods
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Electrophysiological studies
The vectors pcDNA3.1/Zeo+ (Invitrogen) encoding human 7 or C. elegans ric-3 as well as pGEM-T Easy (Promega) encoding acr-16 were used. The vectors were linearised to be used as template for cRNA synthesis with the T7 (pCDNA3.1) or SP6 (pGEM-T Easy) mMESSAGE mMACHINE kits (Ambion). Mature stage IV or V Xenopus laevis oocytes were manually defolliculated after incubation for 1h in 2mg/ml collagenase (Sigma type IV) in calcium-free oocyte saline (OS) (containing (in mM) NaCl, 100; KCl, 2; CaCl 2 , 1.8; MgCl 2 , 1; HEPES, 5 adjusted to pH 7.6 with 5 M NaOH). Following defolliculation, the cytoplasm of each oocyte was injected with 50nl 1ng/nl containing a 5:1 ratio of receptor cRNA: RIC-3 cRNA in RNAasefree dH 2 O. Oocytes were incubated for 2-7 days in filter-sterilized culture medium consisting of OS supplemented with 100 units/ml of penicillin, 100g/ml of streptomycin and 50g/ml gentamycin sulphate and 2.5 mM sodium pyruvate, the medium being changed daily. After 2-7 days incubation, injected oocytes were transferred to a recording chamber (Warner type RC-3Z) for electrophysiological analysis. Oocytes were impaled with two glass microelectrodes (3M KCl, resistance 0.5-1 MΩ in OS) and held under voltage clamp at -100 mV. Standard twoelectrode voltage clamp was achieved using an Axon Axoclamp 900A amplifier under the control of a laboratory PC. Signals were acquired at 1 kHz.
Saline and drugs were applied through a gravity-fed perfusion system (Valvelink 8.2) using computer-controlled pinch valves. With relatively high perfusion rates (5 ml/min), low saline levels in the chamber and a short distance between the perfusion manifold and the chamber, it was possible to achieve consistent amplitude, rapid onset responses in oocytes expressing the rapidly desensitizing α7 and ACR-16 nAChRs. Agonists were applied for 10s, and the effects of allosteric modulators were assessed by applying the drug for 30s immediately prior to a 10s test
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A c c e p t e d M a n u s c r i p t application of agonist in the continued presence of modulator. Agonist challenges were at 3 min intervals to minimize any effects of desensitization. Oocytes were only used in experiments if the amplitudes of responses to successive challenges of agonist differed by 10% or less. All drugs were obtained from Sigma-Aldrich UK except for IVM, PNU-120596 and NS-1738 which were purchased from Tocris (Ellisville, Missouri USA) and acetylcholine chloride which was purchased from Alfa Aesar (Karlsruhe, Germany).
Computational protein modelling and Ivermectin docking
The model of IVM used in this study was constructed using the atom co-ordinates previously determined for avermectin B1a [21] . IVM and avermectin B1a are very similar molecules, differing only at the C22-C23 bond, which is saturated in IVM but unsaturated in avermectin B1a. All IVM atoms conserved in avermectin B1a were therefore assigned the avermectin B1a co-ordinates, leaving only the saturated C22-C23 bond to be modeled. This was readily achieved by simple atom building and local energy minimization with Discovery Studio Visualizer (Accelrys). Figures 2 and 4 were produced using PyMOL (DeLano Scientic).
Modeling of nAChRs was carried out using the molecular modeling software package Sybyl, Automatic Modeling System, In-Silico Sciences, Inc., Tokyo, Japan), originally developed by Ogata and Umeyama [22] . The three dimensional structures of the nAChRs were constructed based on the sequence and coordinates of the standard protein, AChR (2BG9 [23] ) by the simulated annealing method [24] according to Taly et al, 2006 [25] . The receptor model was energy-minimized for 1,000 iterations of conjugated gradients using the MMFF94 force field and A c c e p t e d M a n u s c r i p t MMFF94 partial charges [26, 27] . The coordinates of backbone atoms were fixed during the minimization. The flexible ligand/receptor docking was performed with the FlexiDock, a genetic algorithm-based flexible docking software in Sybyl. IVM was placed manually into the cavity of the ligand binding site. The conformation of IVM was fixed during FlexiDock, except for the torsion angles of the 3-methoxy groups and the sec-butyl group. The docked receptor / ligand models were energy-minimized for 1,000 iterations of conjugated gradients using the MMFF94 force field and MMFF94 partial charges [26, 27] with co-ordinates of the backbone atoms fixed.
Results
Functional studies
Responses mediated by 7 receptors expressed robustly in oocytes in the presence of RIC-3 were reversibly enhanced by both type I and type II allosteric modulators (Fig. 3) . These findings resemble and extend those obtained previously in the absence of RIC-3 [11, 14, 17] . The type I modulators, IVM (30 M), 5-hydroxyindole (1mM), NS-1738 (10M) and genistein (10M), enhanced 7 responses to 123 ± 7 % (n=5), 300 ± 91%, (n=3), 1740 ± 1358 % (n=3) and 376 ± 77%, (n=3) respectively, while the type II modulator, PNU-120596 (3M) enhanced 7 responses by 1867 ± 871 % (n=4). In accordance with previous reports, the type II modulator, PNU-120596 greatly enhanced the duration of the response, while the type I modulators investigated exerted a variable effect upon the time course of the responses, but much less markedly so than type II modulators. The similarity of our findings with type I and type II allosteric modulators and those previously reported [11, 14, 17] also suggests that RIC-3, which 
Computational modelling studies
The structure of IVM used in this study is based on the crystal structure of Avermectin B 1a [21] .
A stick representation of the molecule, based on the published crystal co-ordinates [21] is shown (Fig 2) . Receptor models for the putative transmembrane region were generated and the IVM molecule docked. IVM is so large and rigid that when manually inserted only a limited complex structure was allowed for docking. Also the Flexidock software yielded only one solution as an initial IVM-docked structure. Whatever method was used to obtain the initial complex structure, the resulting complex structures were always very similar. Of particular interest was the finding that the interaction energies for the 7/IVM complex was less than that for ACR16, suggesting that the α7-IVM complex is much more energetically favourable than the ACR-16-IVM complex.
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Discussion
The cys-loop superfamily of ligand-gated ion channel receptors mediate the fast actions of the neurotransmitters ACh, GABA, glycine and 5-HT in humans. These important transmembrane proteins are the targets of major drugs for the treatment of disorders such as anxiety, nicotine addiction, pain, Alzheimer's disease and schizophrenia. Allosteric drug binding sites on these proteins are of growing importance as targets for new drugs, yet their identity remains to be fully elucidated. Here we begin to explore the combination of comparative pharmacology and computational modelling to better understand the human 7 allosteric drug binding site(s).
Major differences in amino acid sequence and the interactions of allosteric ligands between human α7 and C. elegans ACR-16 nAChRs
We show that drugs exhibiting type I (IVM, 5-HI, genistein, NS-1738) and type II (PNU-1205096) PAM activity on human α7 receptor are all without PAM activity on ACR-16, instead displaying varying degrees of attenuation of the amplitude of the ACh response. Genistein and 5-HI result in particularly strong attenuation in the amplitude of ACh responses (Fig. 3) . In line with this, comparisons reveal that despite an overall sequence identity of 47% [20] , human α7 and C. elegans ACR-16 subunits differ at residues known in nAChRs and in other cys-loop receptors to influence the actions of allosteric modulators. For example, ACR-16 differs in 4 of 5 key transmembrane residues, which in rat α7 receptors (these residues are identical in human α7) are known to be important in the actions of the PAMs PNU-120596 and LY-2087101 [15] (Fig.   5) . Also, the short region at the extracellular end of TM2 and part of the inter TM2-TM3 loop region of 7, which was shown to be involved in NS-1738 potentiation [14] , differs by eight amino acid residues when compared to ACR-16.
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A c c e p t e d M a n u s c r i p t Interestingly, the 4 key transmembrane residues highlighted by Young et al [15] (S222 and A225 in TM1, M253 in TM2 and C459 in TM4 after the number in [15] ), which are identical in human and rat α7 but differ in C. elegans ACR-16 and are known to influence PAM activity, are in close proximity to (and in some cases overlap with) residues known to influence the actions of other allosteric ligands in a variety of cys-loop receptors. These molecules include anaesthetics [28, 29] , alcohols [30] , endogenous neurosteroids [16] and androgenic steroids [31] (Fig. 5) .
Three residues in TM1-3, which have been well-characterised in GABA receptors, form a binding pocket with which general anaesthetics can interact [16, 28] . Residues in TM1 and TM4 play a major role in the binding of neurosteroids. Residues already identified as determinants of sensitivity to PNU-120596 [15] , one of the allosteric modulators employed in the present study are among those that differ between ACR-16 and α7.
Computational modelling suggests differences in interaction energies (Energy (Complex)-Energy (Receptor)-Energy (IVM)) between IVM complexes with α7 andACR-16 nAChRs, with the α7-IVM complex being much more stable than the ACR-16-IVM complex (Fig. 4) . Indeed energy considerations suggest that IVM-ACR-16 interactions may be severely limited. However, the small attenuation of the ACh response argues that there must be some interaction between IVM and ACR-16. The sequence differences between 7 and ACR16 invite systematic site-directed mutagenesis studies aimed at elucidating all key residues determining PAM activity and such studies are in progress in our laboratory. Indeed, the valuable insights already gained by comparing 7 nAChRs with a 7 / 5HT3R chimeras [15] encourages the hope that additional insights may be achieved by comparing 7 with ACR16.
Ivermectin can have allosteric and agonist effects on ligand-gated ion channels
Page 12 of 26 A c c e p t e d M a n u s c r i p t IVM acts upon a range of diverse ligand-gated ion channels of both vertebrates and invertebrates, where it can act as an agonist, an allosteric modulator, or both (Table 1 ). In addition to nematode acetylcholine receptors, these targets also include P2X receptors of Schistosoma [32] and of mouse ( [33] ) and histamine-gated chloride channels of Drosophila [34] , as well as nematode [35] [36] [37] [38] and insect [39, 40] glutamate-gated chloride channels, GABA receptors from nematodes to vertebrates [41] [42] [43] [44] and human glycine receptors [45] . There is also evidence for an action of IVM on an intracellular ligand-gated ion channel, the ryanodine receptor [46] . In most cases examined so far, the action of IVM is through an allosteric stabilization of the open state of the channel, but in the case of recombinant nematode glutamategated chloride channels and rat GABA       receptors, IVM can also act as an agonist [43] .
Residues in both transmembrane regions of P2X receptors that affect IVM action have been identified using scanning mutagenesis [32, 47] . Thus IVM exerts a range of actions on diverse members of the cys-loop receptor family and some other ligand-gated ion channels, providing ample scope for identifying the roles of specific amino acid residues in determining IVM action.
Prospects for further understanding of allosteric drug actions and the development of novel allosteric ligands
The use of α7 / 5-HT3A chimeras has begun to elucidate the site of action of PAMs [14, 15] .
Site-directed mutagenesis informed by comparisons of evolutionarily remote members of the α7-like nAChRs (and other members of the cys-loop family of receptors) combined with pharmacological studies and computational modelling, along with access to resolved structures of relatively rigid molecules such as IVM, will complement the work on such chimeras [14, 15] . M a n u s c r i p t and feature annotation were performed using the SWISSPROT database. Although the signal sequence is illustrated, the numbering of residues shown is that of the mature peptide. Fig. 2 . Structure of Ivermectin. The stick model was constructed from the co-ordinates of avermectin B1a [21] . Carbon atoms are coloured grey and oxygen atoms red. Hydrogen atoms have been omitted for clarity. showing residues in transmembrane regions (red boxes, [15] ) and segments between transmembrane regions (yellow boxes [14] ) that are known to mediate the effects of positive allosteric modulators (PAMs). In addition, equivalent residues in other ligand-gated ion channels that have been implicated in the actions of allosteric modulators are also indicated. These sites include a well-characterized binding cavity to which residues in the extracellular portions of TM1-3 contribute. The close proximity of residues in different receptors mediating different allosteric actions suggests that common binding sites are conserved across different members of the cys-loop family. That 7 and ACR16, despite their overall sequence similarity, should 1)
differ at most of these sites, 2) have widely different pharmacologies and 3) robustly form functional homomers underscores the great usefulness of these receptors in exploring the molecular basis of PAM action. Residue numbering is that for the mature peptide. 
